Terms and conditions: semantic complexity and aspirin resistance.
Hennekens
Charles H
CH
Department of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, Miami, USA. profchhmd@prodigy.net
Schror
Karsten
K
Weisman
Steven
S
FitzGerald
Garret A
GA
D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D016022:Case-Control Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D004351:Drug Resistance; D005500:Follow-Up Studies; D014644:Genetic Variation; D006801:Humans; D010349:Patient Compliance; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk; D013928:Thromboxane A2 / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine; D017211:Treatment Failure
D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D013928:Thromboxane A2; C049235:11-dehydro-thromboxane B2; D001241:Aspirin